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Influence of uremia corrected by dialysis on the incidence of neopiasia.
G. B. Piccoli, G. Beltrame, P. Colombo, F. Bonello, R. Boero, C.
Brando, F. Giacchjno, F. Quarello, G. P. Segoloni. Nephrology Units,
S. Giovanni Hospital, Turin, Italy. Two thousand, six hundred and
eighty-five patients of the Regional Registry of Dialysis and Transplan-
tation of the Piedmont Region (RPDT) have been considered. Patients
were divided into 2 groups: Group 1 consisted of 2622 patients neoplasia
free; Group 2, 63 patients affected by neoplasia diagnosed while on
dialysis, since the 6th month of treatment. One hundred and twelve
patients in which the diagnosis of neoplasia was made before the
beginning or before the 6th month of dialysis were excluded. The
demographics were as follows: Group 1, 1497 males, mean age 60.1,
1125 females, mean age 58.6; Group 2,46 males, mean age 60.9, mean
dialysis age at diagnosis 4.1 years, mean interval between diagnosis and
death 8.7 months; 17 females, mean age 59.9, mean dialysis age at
diagnosis 4.5 years, mean interval between diagnosis and death 8,2
months. The analysis has been divided into two parts: in the first some
parameters (age, dialysis age, renal disease, mode of dialysis treatment,
type of neopiasia) were coMpared within the two groups or with the
general population. For age Group I and Group 2 show different
patterns. This is particularly striking in the male, where the age group
55—59, accounting for 14% of Group 1, accounts for 26.5% of Group 2.
A relatively low prevalence was found over 65 years of age. For type of
neoplasia, lung and breast cancers are, in male and female, the most
common. A percentual increase of gastroenteric neoplasia was found,
while kidney and skin tumors and leukemia-lymphomas were not
increased. In renal disease, no significant difference was found between
the two groups. Worth mentioning is that 11% of the tumors were
diagnosed in polycystic kidney patients (9% of the general dialysis
population). In the mode of treatment category no significant difference
was found between Group 1 and Group 2. But for dialysis age, the
distribution of the two groups is quite different, Group 2 showing a
tendency of clustering around the 3rd—Sth year of treatment, while the
peak of Group I is at the second year. In the second part of the study
only patients started on dialysis in the period 198 1—1986 were consid-
ered, and the Relative Risk (RR) was calculated, employing data from
the Tumor Registry of a neighbor Northern Italy Region (Tumor
Registry of the Lombardy Region). Dialysis patients were divided into
subgroups for age and dialysis age. Age RR was 2.8 for the patients
started on dialysis at 40—49 years of age, and decreased thereafter (1.6
for the age group 50—59, 0.7 for the age group 60—69, no neoplasia was
diagnosed in patients over 70). In dialysis age, RR was calculated
separately for patients 1 to 69 and over 70 years of age, both groups
further sorted for dialysis age. While in the first 2 years of treatment, in
the subgroup 1 to 69 years of age, the RR was I, it increased gradually
during the 2nd to 4th year (2nd year: RR = 1.1; 3rd year: RR = 1.5; 4th
year: RR = 2). In conclusion, risk of developing a neoplasia is increased
in some subgroups of dialysis patients; patients at increased risk are
quite "well doing": they are relatively young, less affected by compet-
itive causes of death, and have thus a long life expectancy; their dialysis
age is a3 years.
Intracellular calcium as a possible cytoplasmic inhibitor of membrane
pump in normotensive and hypertensIve subjects. P. Delva, C.
Lechi, A. Lechi, C. Capra, P. Minuz, and L. A. Scuro. Institutes of
Clinical Medicine and Chemistry and Clinical Microscopy, University
of Verona, Italy. It is known that Ca2 inhibits the Nat K pump and
the Nat, K1- ATPase of human red blood cells. We investigated the
importance of this possible regulatory mechanism in a group of healthy
donors (N = 9) and in essential hypertensive patients (N = 13).
Essential hypertension is a condition in which both a deficiency of the
Nat, Kt pump and calcium handling abnormalities resulting in elevated
concentrations of LCa211 have been described. We measured intracel-
lular calcium ([Ca2t]j) in platelets utilizing the fluorescent indicator quin
2 and the Na+, Kt pump in erythrocytes as ouabaln-sensitive Kt influx
at different extracellular potassium concentrations. The maximal veloc-
ity of ouabain-sensitive Kt influx (Kt influx was only slightly
lower in essential hypertensives (EH), but not significantly different
from normotensives (NT) (mean s: 6.027 1.519 vs. 6.175 1.020
mmol Ktlliter cells/hiT'), while [Ca21, was slightly elevated in EH as
compared to NT (mean six 150 35.2 vs. 126 21.6 nM; P < 0.05).
A highly significant inverse correlation was found in EN and NT, taken
together, between [Ca2t]1 and Kt influx V,,, (N = 22, r = —0.727; P
<0.001). This inverse correlation was still present if EN and NT are
considered separately. These preliminary data confirm that [Ca2t], is
relatively elevated in EN patients in agreement with other reports.
Even though for technical reasons we were obliged to use different
cellular models, our data show that [Ca21, may play an important role
in the regulation of the membrane Nat, Kt pump by acting as a
cytoplasmic inhibitor. Nowever the role of this mechanism in EN
patients, where the Nat, Kt pump appears normal, has still to be
elucidated.
Correction of coagulation disturbances in chronic bemodlalysis patients
treated with human recombinant erythropoietin(rHuEPO). S. Casati, P.
Passerini, M. Moia, G. Graziani, P. M. Mannucci, C. Ponticelli,
Divisione di Nefrologia and Centro Bianchi-Bonomi per lo studio della
Emofilia e della Trombosi, Ospedale Maggiore Policlinico, Milan,
Italy. The efficacy of rNuEPO in correcting coagulation abnormalities
was investigated in 10 chronic hemodialysis patients (mean age 45 11
yrs; mean dialysis duration 8.4 6 yrs). rNuEPO was given intrave-
nously at the end of each hemodialysis at increasing doses, starting with
24 p1kg to 432 p1kg body weight, to reach full correction of anemia (Hb
10-12 g/dl) over a period of 14 2 weeks. Predialysis bleeding time (BT)
was tested with a template like disposable device (Simplate II) at
baseline and at different Nb concentrations. At baseline (A) mean Nb
was 6.2 0.8 g/dl (Nt 19 2%). Mean bleeding time was 21.8 10
minutes. BT was longer than 30 mm in 5 patients, and within the normal
range (3—7 mm) in one. After partial correction (B) of anemia (Nb 9.4
I g/dl; Nt 29 3%) BT had shortened to 10.4 7 mm (P < 0.005). Full
correction of anemia (Nb 11.8 I g/dl; Nt 37 3%) led to a further
reduction of BT to 8.3 4.3 mm (Pc 0.001 vs. A and P <0.05 vs. B).
In one patient BT shortened from 30 mm to is mm, only. One patient,
with normal baseline BT, who did not respond to rNuEPO was
excluded from the study. When full correction of anemia was obtained,
antiplatelet therapy (aspirin 100 mg/day) was given to all patients.
Nevertheless, a cerebral ischemic lesion in one patient (Nb 12.2 g/dl)
and thrombosis of the artero-venous fistula in another (Nb 11.7 g/dl)
were observed, It is concluded that rNuEPO corrected anemia and
almost normalized BT in 8 of 9 patients who concluded the study. Our
data confirm the existence of a reciprocal relationship between hema-
tocrit and bleeding time. Improvement of anemia and of BT can expose
the patient to higher risks of thrombotic accidents; thus, a too rapid and
complete correction of anemia should be avoided in older patients, in
long term dialysis and in hypertensive patients who are already at high
risk of atherosclerosis.
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Human recombinant erythropoietin effects on anemia in chronic hemo-
dialysis patients. S. Casati, P. Passerini, G. Graziani, C. Ponticelli,
Divisione di Nefrologia, Ospedale Maggiore Policlinico, Milan, Italy.
In 14 anemic patients on regular hemodialysis (age 45 11 yrs) the
safety and the efficacy of human recombinant erythropoietin (rHuEPO)
were investigated. rHuEPO was given intravenously at the end of each
hemodialysis starting with the dose of 24 p/kg of body weight. Doses
were doubled every two weeks until a Hb increment of at least 2 g/dl
was obtained. Then, doses were increased by 24 p/kg every two weeks
until full correction of anemia was reached (Hb 10—12 g/dl). The 2 gIdl
increment was reached in 2 patients at the dose of 24 p/kg, in 7 patients
at the dose of 192 p1kg and in the remaining 5 patients at the dose of 384
p/kg. In 13/14 patients Hb rose from 6.2 0.8g/dl to 12.2 1.3 gIdl (P
<0.001) in 14 2 weeks. In the last patient a Hb increment of 1.3 g/dl
was observed despite prolonged administration of high doses of
rHuEPO (384 p1kg). Iron supplementation was given i.v. to 12 of 14
patients (mean 1001 461 mg Fe3), Nevertheless, plasma iron levels
could be only partially corrected. In 3 patients, shivers, fever, sweating
and abdominal cramps ensued 90—120 minutes after rHuEPO injection
and spontaneously disappeared 9—10 hours later. In eight previously
hypertensive patients the correction of anemia was accompanied by
increase in mean blood pressure (109 9 vs. 115 9 mm Hg). Blood
pressure did not change in normotensive patients. Predialysis plasma
potassium levels increased from 5.4 ito 5.9 I mEq/liter, exceeding
7 mEq/liter in 3 patients. Plasma bilirubin, which was in the normal
range in all patients before treatment, during rHuEPO treatment
showed an increment of its unconjugated fraction (from 0.64 0.3 to
1.4 0.4 mg/dl) in the hepatitis B antigen positive patients. It is
concluded that rHuEPO corrects uremic anemia in most dialysis
patients. The increased number of red cells which are daily hemolysed
can explain the rise in plasma potassium and the high levels of bilirubin
observed in hepatitis B antigen positive patients, which may have a
potentially reduced liver function. In hypertensive patients the correc-
tion of anemia can be countered by the worsening of hypertension
which can reach clinical significance.
The renal injury in patients undergoing abdominal aneurysm repair.
G. Graziani, G. Carabellese, E. Lorenzano, M. Zanetta, A. Morganti,
A. Benigni, S. Casati, Nefrologia Osp. Maggiore, Anestesia 1st. Gun.
Perf., Chir. Vasc, Univ. Gun. Med. Univ. Milano, 1st. Ric. Farm. M.
Negri Bergamo, italy. Despite multiple advances in the management of
critically ill patients, acute renal failure (ARF) complicating aortic
aneurysm surgery continues to have a high mortality rate. The knowl-
edge of the biohumoral factors impairing renal function before, during
and after surgery is crucial for a correct prevention of ARF. In 20
patients undergoing abdominal aneurysm repair, with normal preoper-
ative plasma creatinine levels, submitted to the same preoperative
plasma volume expansion and anesthesia, the urinary excretion of
thromboxane (TxB2), the urinary/plasma ratio of urea and creatinine
(UfP urea and creatinine), the fractional Na excretion % (FENa%), the
plasma levels of renin activity (PRA ng/mllhr), epinephrine (EP pg/mi),
norepinephrine (NE pg/mI) were checked before the induction of
anesthesia, after aortic infrarenal declamping, at the recovery from
anesthesia and 2, 6, 24 hours after the end of the surgery. The results
are reported in the table.
U/P
Urea
U/P
Creat.
FENa
%
PRA
ng/ml/hr
Bas.
Rec.
2 hr
24 hr
40.2 18
19.8 12
13.8 a
25.5 13
108.8 40
54.0 32
33.2 2r
70.7 28
1.0 0.5
1.2 0.8
2.3 0.51
0.7 0.3
0.7 0.1
2.9 0.8"
2.0 0.6
3.2 0.8
NE
pg/ml
EP
pg/mi
TxB2
ng/hr
Bas.
Rec.
2 hr
24 hr
246.1 25
817.4 544k
410.4 124
402.4 60
38.4 6.7
163.3 56
151.5 66
50.6 12
9.3 2.3
119.6 33
i%.6 5o
35.1 7.8
a p < 0.001bp< 0.005
Our results show that infrarenal aortic clamping and declamping
manoeuvers activate several vasoconstrictive factors, above all at the
end and 2 hours after surgery. It is conceivable that these factors can
expose to a functional ARF. In order to prevent the risk of oligoanuria
is recommended to try the use of drugs inhibiting the synthesis of these
vasoactive agents.
Vitamin 1) metabolites after renal transplantation. G. Graziani, S.
Adami, A. De Vecchi, V. Bra go, R. Zubani, S. Casati, C. Ponticeili,
Nephrology Division, Ospedale Maggiore, Milano and Semeiotica
Medica, University of Verona, Italy. To compare the effects of
azathioprine (Aza) or cyclosporine (C5A) on tubular 1 aand 24-hydroxy-
lase activity, the 250H, 1, 25(OH)2 and 24, 25(OH)2 D3 plasma levels
were measured in 17 stabilized renal transplant (Tx) patients, before (B)
and after (A) an acute oral load of 25 (OH) D3 (150 pg/day for 15 days).
Twelve out of 17 patients were treated with CsA and steroid (MP), 5
with Aza and MP. Results are reported in the Table as means
standard errors:
25 OH D3 I ,25(OH)2D3 24,25(OH)2D3 PTH
Aza ÷ MP B 49.7 12.7
A 456.0 145.5
12.5 4.2
19.0 4.3
1.9 0.4
16.1 4.2
0.6 0.1
0.5 0.1
CsA + MP B 21.4 10.0
A 68.6 20.7
9.7 6.5
8.2 5.1
1.6 0.9
8.1 2.6
0.5 0.1
0.5 0.1
Normal 5—40 ng/ml 20—70 pg/mI 0.3—3 pg/ml 0.6
1ev.
Patients' compliance to the therapy was confirmed by 25 (OH) D3 raised
plasma levels. No significant differences were observed in basal plasma
levels of vitamin D dihydroxylated metabolites. 1, 25 (OH)2D3 raised in
all Aza + MPand in 3/12 CsA + MP, whereas it decreased or remained
undetectable in 9/12 CsA + MP patients. 24, 25 (OH)2D3 was signifi-
cantly raised (P < 0.01) in all the patients. CsA seems to inhibit
selectively the 1 a- and to have no influence on the 24-hydroxylase
activity. In CsA patients, the administration of 25(OH)D3 did not
increase la-hydroxylation. These preliminary data suggest that long-
term CsA treated patients may be exposed to an increased risk of
osteodystrophy.
Effects of acute renal failure on DNA synthesis and DNA polyinerase
activity of rabbit liver nuclei. B. Di Paoio, T. Di Marco, P. F. Palmieri,
G. Del Rosso and A. Albertazzi, Institute of Nephroiogy, University of
Chieti, Italy. A decreased enzyme activity, an impaired constant of
affinity and perhaps of the number of enzymatic molecules are charac-
teristic findings of uremia, but experimentally the search for this
reduction has not been satisfying at all. Furthermore, no one experi-
mental work has supported the possibility that an inhibition of animals
liver nuclei DNA synthesis is caused by "uremic toxins". In five
female, white New Zealand rabbits (3.5—5.5 kg) the liver was removed
2 days after a surgical nephrectomy, weighed and dissected into small
pieces. The nuclei were prepared according to Smith and Bererezney,
while DNA synthesis assay and the activity of DNA-polymerase were
performed according to L. Tarrago-Litvak. Purified nuclei from uremic
animals showed a decreased level of DNA synthesis as compared with
nuclei from 5 control animals (25.50 10. 15% vs. 105.40 3.80%, P <
0.001). The DNA-polymerase activity was 65.50 8.70% vs. controls
(P <0.001) for native DNA, and it was 61.20 7.40% of controls with
activated DNA (P < 0.001). In acute renal insufficiency many clinical
effects observed are caused by the reduction of some fundamental
enzymatic activities. Our study was designed to demonstrate that DNA
synthesis and polymerase activity are reduced in acutely induced
uremia. Many factors are doubtless responsible: endocrine abnormali-
ties, pathologically retained metabolites. In other words, acute uremia
seems to be responsible for an intranuclear and a cytosolic, extracellu-
lar derangement as well. Thus, the "uremic toxins" could filter into the
nuclear wall, modifying the enzymatic pool and the proteosynthetic
activity of the cells.
Influence of pKa in the evaluation of dialysate bicarbonate. M. Feriani,
S. Biasioli, L. Bra gantini, A. Brendolan, S. Chiaramonte, R.
Dell'Aquila, A. Fabris, M. Milan, C. Ronco, G. La Greca, Dept. of
Nephrology, St. Bortolo Hospital, 36100 Vicenza, Italy. For a proper
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evaluation of base balance in hemodialysis (HD), the total CO2 (TCO2)
measurement is needed. TCO2 is composed of HCO3 and dissolved
C02, but only the former is really a buffer, while the latter is neutral.
Thus, to exactly divide the two components, not only the pH hut also
the actual pK (pKa) of the solution must be known. The automatic
hemogasanalyzers (HGA) are based on the assumption that pK is a
constant (6.10), while dialysate pK is largely different from blood pK.
The study has been performed on 1/6 ai NaHCO3 solution (diluted 1:5
= 20 samples), on inflowing (20 samples) and outfiowing (20 samples)
bicarbonate dialysate for standard lID. On each sample pH, pCO2
(HOA Radiometer ABL 3), TCO2 (Coming 965 TCO2 Analyzer = CA)
and pKa (derived from ionic strength) were obtained. Table shows the
results.
1/6 M 1:5
THCO3S
33.4
HGA
41.6 0.8
S'
+24.5%
CA
33.1 0.6
Ab
—0.9%
Infiowing 31 28.5 1.3 —8.1% 29.4 0.7 —5.3%
Outfiowing — 28.0 0.5 — 29.8 0.5 —
a Theoretical HCO3
b Difference from T % HGA-pK 6.10; CA = mean pKa 6.145
These data confirm that a careful evaluation of dialytic bicarbonate
must take into account the pKa of the fluid. pKa changes—even small—
could lead to large variation in bicarbonate measurements.
TCA cycle IntermedIates In chronic renal failure. S. Biasioli, M.
Feriani, L. Bigi, A. Brendolan, L. Bragantini, A. Fabris, C. Ronco, S.
Chiaramonte, G. La Greca, Dept. of Nephrology, Vicenza and
Legnago, Italy. It is well known that amino acid, lipid and glucose
metabolisms are deranged in uremic people. Their final products
converge to the Krebs cycle, which can be defined as the "crossing" of
several metabolic pathways. On plasma fasting samples several inter-
mediates of TCA cycle were determined (by means of HPLC) in 18
subjects with normal renal function and in 21 CRF (serum creatinine =
11.2 3.6 mg%). The table shows the obtained results: all values are
expressed (jxM/liter) as mean 5D. Student's t-test for unpalred data
was applied.
Controls CRF P
Citrate 5.06 1.78 8.13 4.08 <0.05
ochetoglutarate 2.07 1.25 13.46 22.99 NS
Fumarate 0.13 0.08 0.41 0.24 <0.001
Malate 9.58 3.94 33.08 18.83 <0.001
Oxalacetate 1.94 2.86 7.89 8.85 <0.01
The overall pattern resulting from these data is similar to that observed
in rat skeletal muscle during exercise. Replealshment of citic acid
intermediates could in theory occur via several anaplerotic reactions
that probably play a role during exercise and possibly in uremics.
Another theory suggests the possible existence of a relationship be-
tween the TCA cycle and some aminoacids, namely aspartic acid and
alanine. Uremia and ischemia have an equivalent pattern: aspartate can
generate alanine involving oxalacetate and malate.
Antiprotelnurlc effect of Indomethacin (md.) in passive Heymann
nephrltls (PEN) in rats. C. Zoja, A. Benigni, P. Verroust, P. Ronco, T.
Benani, and U. Remuzzi, Mario Negri Institute for Pharmacological
Research, Bergamo, Italy and INSERM U64, Hopital Tenon, 4 Rue de
Ia Chine, Paris, France. md. has been used to reduce protcinuria in
nephrotic syndrome patients with controversial results. The mechanism
of action has not been established. The objectives of the present study
were: 1) to verify whether md. influences protein excretion in an
experimental model of immunologically-mediated glomerular disease;
2) to establish whether the possible beneficial effect of md. is a
consequence of a reduction in glomerular filtration rate (OFR); 3) to
establish the possible association between the antiproteinuric effect of
md. and its inhibitory action on the renal arachidonate metabolites; 4)
to study the relationship between protein excretion and renal synthesis
of thromboxane (Tx). We used an immune complex disease, PHN
induced in the rat by i.v. injection of heterologous serum directed
against a brush border component (gp 330 antigen). md. (6 mg/kg i.p.)
administered for 4 consecutive days to rats with PHN in the period of
heavy proteinuria, significantly (P < 0.001) reduced protein excretion
(67.52 19.49 after the treatment vs. 221 61 mg/day before). The
reduction in protcinuria was not a consequence of a reduction in OFR
as measured by inulin clearance (0.84 0.20 in PHN rats given lad. vs.
0,94 0.04 mI/mm/lOU g in PUN untreated rats). Isolated glomeruli
from PHN rats studied 16 days after anti-gp 330 serum injection
generated significantly (P < 0.01) more TxB2 than normal glomeruli
(0.47 0.10 vs. 0.21 0.05 ng/mg prot/hr). Urinary excretion of TxB2
was also significantly (P C 0.05) higher in rats with PUN than in normal
rats (34.09 8.19 vs. 24.31 7.43 ng/day). md. reduced the urinary
TxB2 excretion by 74%. In contrast the selective Tx-synthase inhibitor
UK-38,485 given to PUN rats at a dose fully inhibiting platelet TxA2
synthesis, only partially (around 40%) inhibited urinary excretion of
TxB2 and did not reduce protcinuria. These results provide the exper-
imental hasis for the observed antiproteinuric effect of md. in humans.
Peroxidation of polyunsaturated fatty acids In the red blood cell
membranes: Its role in causing anemia in uremic patients in chronic
hemodialysic. Taccone-Gallucci M., Lubrano R., Bandino D., Tozzo C.,
Elli M., Mazzarella V., Meloni C., Morosetti M., Giardini D. and
Casciani C. U., Clinica Chirurgica, II Universitd degli Studi di Roma,
Clinica Pediatrica, I Università degli Studi di Roma, Rome, Italy.
Recently we have demonstrated that peroxidation of polyunsaturated
fatty acids (PUPA) is increased in the red blood cell (RBC) membranes
from uremic patients (pts) in chronic hemodialysis. PUFA peroxidation
induces production of short chain aldehydes. Among these,
malonildialdehyde (MDA) can be specifically dosed and is therefore an
useful index of peroxidative damage. MDA is toxic for the RBCs, as it
forms high molecular weight aggregates between membrane proteins
and PUPA in the phospholipidic fractions of phosphotidylserine and
phosphotidyl-ethanolamine. Furthermore, high concentrations of MDA
block the NaIK pump by blocking membrane ATPases. Both events
induce lesser deformability of the RBCs, with increased susceptibility
to hemolysis. Vitamin E is the most important membrane antioxidant
system and its administration to hemodialysis patients induces signifi-
cant reduction of peroxidative processes and increase of hematocrit
(Uct). The purpose of this study was to verify the possible correlation
between reduction of peroxidation induced by treatment with a-
tocopherol and changes in plasma concentrations of free hemoglobin
(Ub), one of the manifestations of hemolysis. Nine hemodialysis
patients were administered 300 mg of vitamin E i.v. daily for 15 days.
Before and after the 15 day treatment we studied RBC MDA,
intradialytic percent variation of plasma Hb (4%), and Hct.
Before
treatment
After
treatment P
MDAmg/rnlofpackedRBC 6.19 1.29 0.69 0.13 0.0005
Hb A % intradialytic 150.78 82.71 50.00 24.65 0.0005
Hct 23.27 4.72 29.44 3.80 0.005
Our results show that reduction of PUPA peroxidation in the RBC
membranes induced by vitamin B administration is accompanied by
increase of Net and reduced intradialytic production of free plasma Hb,
that is, reduced hemolysis. We therefore believe that administration of
vitamin B is helpful in reducing chronic hemolysis and therefore in
treating anemia in uremic patients on chronic hemodialysis.
Peritoneal membrane ccleroslng: Role of plastIcIzers. A. Fracasso, U.
Coli, S. Landini, P. Morachiello, F. Righetto, F. Scanferla, R. Genchi,
and G. Bazzato. Nephrology and Dialysis Department, Umberto I
Hospital, Venice-Mestre, Italy. Peritoneal membrane (PM) sclerosis
with loss of ultrafiltration (UP) capacity is considered a serious com-
plication of long-term CAPD treatment. Plasticizers (PL) leaking from
plastic devices may be one of the possible causes of this anatomo-
functional alteration of PM. We studied the effects of intraperitoneal
(IP) PL injection of three different compounds di-2-ethylhexyl-phtalate
(DEHP), didodecylphtalate (DIDP) and benzylbutyl-phtalate (BBP).
Six rats weighing 350 to 500 g underwent 5/6 renal ablation and injected
with the 3 PL at dosages of 300 mgm/kg body wt over a period of 7 days,
and then subjected to CAPD (3 cycles with 1.5% and 3 with 4.25%
bottled solutions). The controls were 3 normal renal function (N) rats,
IP injected with the same amount of PL. Three animals were also
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studied by using a DEHP lower dose (3.6 mgmlkg body wt). The results
showed a marked decrease in UJ in CRF animals respect the N-rats:
0.6 0.08 and 1.66 0.07 mI/cycle, respectively for DEHP, with a
decrease of the same magnitude by using lower doses: 0.36 0.07 and
1.57 0.13 ml, respectively (P < 0.001). The same behavior was
observed in the groups with other PL. The PM of these animals was also
studied at light (LM) and scanning electron microscopy (SEM). The LM
showed a thickening of PM in almost 70% of the explored area, while in
the normal rats no more than 5—10% presented the same feature. At
SEM in the CRF rats a disappearance of the microvilli was noted, We
can conclude that the PL play an important role in the pathogenesis of
the PM sclerosis.
Oxydative metabolism of polymorphonuclear granulocytes in chronic
renal failure under conservative management. A. Spattini, L. Lucchi,
M. A. Acerbi, G. Cappelli, E. Lusvarghi, Cattedra e Divisione di
Nefrologia-Servizio di Emodialisi Ospedale Policlinico, Modena, Italy.
During phagocytosis or in response to soluble stimuli oxydative metab-
olism of polymorphonuclear granulocytes (PMNG) significantly in-
creases from a basal condition and produces various highly reactive
oxygen-free radicals which emit light or chemiluminescence (CL). The
oxydative metabolism of PMNG was evaluated in 26 patients, 12 of
whom with initial renal failure (creatininemia 2—3 mg/dl) and 14 of whom
with advanced renal failure (creatininemia 10 mg/dl); the control
group consisted of 26 healthy subjects. No statistically significant
difference (P> 0.3) was found between the control group and the group
with initial renal failure. On the other, in the group with advanced renal
failure the oxydative metabolism of PMNG showed a significant in-
crease (P < 0.01) in the basal condition; and a significant decrease (P <
0.01) during phagocytosis. The marked vulnerability to infection of the
uremic patient may be partly accounted for by the depressed cell
immunity expressed in our results. The alteration in oxydative metab-
olism of PMNG in advanced renal failure may be interpreted as follows:
the ammonia levels produced during uremia lead to production of an
ammonia derivate of C3 able to constantly stimulate the oxydative
metabolism of PMNG in basal condition; during phagocytosis, how-
ever, the reduced oxydative metabolism of PMNG in uremic as
compared to healthy subjects can be correlated with retention of
phenols, indoles, thioles and urates.
Use of a genetic marker for the diagnosis of adult polycystic kidney
disease in northern Italy. L. del Senno, A. Castagnoli, I. Maestri, E. De
Paoli Vitali, G. L. Limone, S. Soffritti, and A. Farinelli. Centro Morbo
Cooley, University, Nephrology and & Radiology Depts., S. Anna
Hospital, Ferrara, Italy. Recently the locus for the adult polycystic
kidney disease (APCKD) has been reported to lie on the short arm of
the chromosome 16. This result has been obtained by studying APCKD
families of Northern Europe, where the disease is coinherited with a
highly polymorphic DNA probe of the chromosome 16 (3' HVR)
(Reeders et al., Nature 1985). In order to verify if the 3' HVR locus is
in linkage also to APCKD of other populations, this probe has been
used to investigate the disease in Northern Italian population, where the
disorder appears in the common form and with a high incidence
accounting, in some areas, for the 40% of dialysis patients. PvuII
RFLPs of 3' HVR DNA have been analyzed in 11 APCKD families. The
allelic fragments range from 1.8 Kb to 6 Kb in size, with a distribution
different from that reported for the Northern Europeans and with a
lower heterogeneity (85% of the investigated subjects are heterozy-
gous). The families (two of which extended) were all informative for the
linkage analysis. Only one recombination between 3' HVR allele and
APCKD has been observed out of 42 meioses. Moreover, by RFLPs
analysis, 5 at risk APCKD individuals, two under 10 years, have been
correctly predicted APCKD positive, as later confirmed by ultrasonog-
raphy. In conclusion, data obtained demonstrate that the APCKD in
Northern Italy is in linkage to the 3' HVR locus as in Northern Europe
population, thus suggesting a monogenic nature of the disease. There-
fore the 3' HVR probe can be used for presymptomatic or prenatal
diagnosis of the disease in this country. Work was supported by Italian
CNR, Progetto Finalizzato Ingegneria Genetica e Malattie Metaboliche
Ereditarie, and by Regione Emilia-Romagna,
Desferrioxamine infusion test (DFO Test): Identification of explanatory
variables. M. Andriani, A. Piccoli, M. Nordio, P. Gilli, D. Brancaccio,
Nephrology Units of Dolo, Ferrara, Milano and of the University of
Padova, Italy. The DFO test was proposed in recognizing dialysis
patients with increased aluminum (Al) stores. We submitted 107
unselected dialysis patients to DFO test in order to identify the
variables accounting for the test results. Basal Al serum level (A1B), Al
serum level after DFO (A1D), age, dialytic age (DA), diuresis, body
weight, PTH, serum proteins (SP), hematocrit (Ht), MCV, iron (Fe),
ferritin (FER) and presence of HBsAg were considered. AIB resulted
highly correlated with AID (r = 0.85, P < 0.001) and AID-A1B () (r =
0.68, P < 0.001). Between the two groups of patients obtained consid-
ering the threshold 180 jsgfliter for i, there was a significant difference
(t-test) in mean values of A1B, AiD, Ht, Fe, FER and SP. A discrimi-
nant analysis (in stepwise) performed on all variables allowed a correct
allocation of the 88% of the patients into the two groups with the
following discriminant function (standardized coefficients): 0.85A1B +
0.48DA + 0.26 PTH. It is concluded that: (i) A1B is the most important
variable accounting for DFO results with a twice as large a weight than
DA and three times that of PTH; (ii) the other factors differentiating the
two groups at the univariate statistical analysis become useless when
evaluated after allowing for the effects of A1B, DA and PTH with the
multivariate approach; (iii) the discriminant score could be a useful
device in the follow-up of the single patient in evaluating the rate of A!
overload without DFO test.
Impaired axonal conduction in the uremic neuron disease. A.
Albertazzi, B. Di Paolo, T. Di Marco, L. Di Filippo, D. Viola, Institute
of Nephrology, University of Chieti, Italy. It is well known how uremia
can induce an impaired transmission of nervous impulse along nerve
and muscle cells, a delay through the synapses whereas the nerve-
muscle junctions are involved as well. Up to now it is hard to say if this
neuro-junctional involvement is dependent from the axonal endings or
from the neurochemical mediators. The aim of our study was to
determine whether the impairment of axonal conduction has a role in
the pathogenesis of the motor-sensitive uremic nerve disease. Fifty-one
patients in ESRD (GFR: 15.20 6.80 ml/min/l.73 m2) and 32 on RDT
were studied for Somatosensory Evoked Potentials (SEP) and analyzed
for the Electrospinogram (ESG), Spinal Cord Velocity (SCV) and
Central Conduction Time (CCT). The slowest nervous conduction
occurred in the posterior root ganglia of T cells (24.50 6.30 m/sec vs.
32.30 5.80 rn/sec, P < 0.001); in 29 (34.93%) the motor and sensitive
conduction was found in the normal range. The chance that a normal
conduction could be found moving forward from the posterior root
ganglia increased, keeping in exam the SCV (30.10 3.20 rn/sec in the
uremic vs. 33.50 4.80 m/sec of controls, P < 0.001) and the CCT (5.7
0.90 msec of uremics vs. 5.3 0.85 of controls, P < 0.005). The
uremic neuropathy is a "dying-back syndrome" as already known, but
the most important finding of the present study is the much more
proximal distribution of the slowing of the nervous conduction.
It remains established that the impairment of the conduction velocity
is primarily proximal and distal in a latter time. It is reasonable sup-
pose that the neurotropism of uremic toxins occurs mainly on the
nuclear structures of the cell (perycarion, Nissl's substance and endo-
plasmic reticulum) and that this picture can be modified or completely
reversed.
Morbidity in hemodialysis patients, protein catabolic rate, adequacy of
dialysis. C. Andreotti, A. Valentini, Div. Nephrology and Dial., Section
of Physics, St Chiara Hospital, Trento, Italy. The purpose of our study
was to assess the relative impact of nutrition and dialysis prescription
on hemodialyzed patients' morbidity. Using a program of urea kinetics,
for this purpose written on computer, at the beginning of 1986 we
calculated in a group of 61 patients the following data: pcr (normalized
protein catabolic rate) as a measure of dietary protein intake; TACurea
(time averaged urea concentration); Kt/V as an index of adequacy of
dialysis, where Kt = Kd (dialyzer clearance) x td (treatment time) and
V = urea distribution volume, with V calculated from the urea kinetics.
A year later we evaluated the incidence of hospitalizations (excluded
those for vascular access problems) in the group with pcr below 0.8
g/kglday (group 1) and in the group with pcr above or equal to 0.8
g/kglday (group 2), the respective TACurea and Kt/V.
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group 1 group 2
no patients 23 38
TACurea mg/dl 32.3 (SD 9.8) 42.6 (SD 6.9)
KtJV 1.1 (SD 0.3) 1.4 (SD 0.3)
Hospitalizations 1.9 (SD 1.9) 0.7 (SD 1.0)
no/pt/yr
-
Since morbidity in dialysis patients is influenced by age, time on dialysis
and other concomitant clinical problems we compared two subgroups of
19 patients each, well matched for age, time on dialysis and free of
extrarenal complications.
per < 0.8 per  0.8
no patients 19 19
age yr
time on HD months
62.5 (SD 7.6)
54.6 (SD 34.8)
62.1 (SD 6.4)
54.2 (sn 49.6)
TACurea mg/dl 31.5 (SD 14.7) 43.4 (SD 11)
KtJV 1.2 (SD 0.3) 1.3 (SD 0.3)
Hospitalizations 1.7 (SD 1.0) 0.7 (SD 0.8)
no/pt/yr
In conclusion, morbidity was found significantly more elevated in the
patients with low per in the group at large as well as in the subgroups.
Protein dietary intake is of key importance in morbidity of HD patients
even if KtJV is in the range indicated by Gotch (1 to 1.3) and
corresponding in our low per group to TACurea of 32.3 (SD 9,8)mg/dl.
Amylold arthropathy in patients on RDT: A widespread disease. A.
And/i, P. Padovese, R. Damasso, M. Gallieni, C. Cavagnino, G.
Airoldi, M. A. Buschetti, G. Colantonio, R. Rossi, D. Brancaccio, Osp.
S. Paolo, Milano; Osp. Borgomanero, Osp. Como., italy. Amyloid
arthropathy is a newly discovered complication observed in patients on
RDT. However the frequency of this disease is still unknown, In this
study we present the radiological evaluation of 286 patients treated in
three different dialysis units. The most relevant X-ray aspects were
cystic radioluciences of bone which were interpreted as having resulted
from local amyloid deposition involving carpal bones, homeral and
femoral heads as main targets. The Table shows that X-ray findings,
where 1, 2, 3 represent the different renal units:
Ho- Femo-
Carpal meral nil CTS
bone head head no S.P.
No pts no (%) no (%) no (%) (%) no (%)
1) 35 5(14) 11(31) 4(11) 1(3) 4(11)
2)138 30 (22) 42 (30) 17 (12) 7 (5) 55 (40)
3)113 14(12) 29(26) 7(6) 10(9) 26(23)
CTS, earpal tunnel syndrome, S.P., shoulder pain
In 3 out of these patients amyloid depositions were also find at earpal
tunnel. In 2 out of 3 other patients synovial biopsies showed amyloid
which was identified related to beta2-microglobulin (thm) deposition,
using an immunocytoehemical analysis at the electron microscope. In
conclusion anyloidosis is a frequent complication of RDT patients, and
/32m deposits are an ubiquitous finding even in patients without any
clinical symptoms.
Erythrocyte ferritin: A new index of iron requirement in patients on
chronic hemodialysis (CHD). C. Brunati, A. Piperno, 0. Civati, C.
Guastoni, M. L. Perrino, U. Teatini. A. Perego, B. Brando, L. Minetti,
Renal Unit, Niguarda Ca' Granda Hospital, C/mica Medica iii,
University of Milan, Milan, Italy. It is generally assumed that serum
ferritin (SF) is the best index for monitoring iron balance in CHD
patients because of its good correlation with bone marrow iron. In
contrast, it is not yet clear if S is a good predictor of the response to
iron therapy. Recently it has been found that ferritin content of red cells
is measurable, reflects the balance between iron supply to erythroid
marrow, and its utilization may be a useful parameter to disclose the
real iron need in patients with increased or reduced red cell turnover. 5r
and erythrocyte ferritin (EF) were evaluated in 35 CHD patients, 45
healthy subjects (HS) and 22 non-nephropathic, iron deficient females
(IDF). In HS mean SF and 64 pg/liter (range 13-300) and mean EF was
9.2 ag/cell (range 4-39.5). In IDS mean S was 11 pg/liter (range 2-30)
and mean EF 1.6 ag/cell (range 1.2-5). In CHD patients mean S was
149 pg/liter (range 8-3980) and mean EF was 19.8 ag/cell (range 2-128.8).
25 CHD patients with basal S <500 jig/liter were orally treated with
200 mg of Fe + for 2 months. The table shows the number of
responders (r) to the therapy (Hb increase of 1 g/dl) in CHD patients
grouped according to basal S and EF levels:
S pg/I r EF ag/cell r
8-47(N=8) 3 2-9(N=7) 5
54-150 (N = 8) 2 9-72 (N = 18) 0
171-497 (N = 9) 0
In conclusion, basal S levels could not always uncover patients with
iron deficient erythropoiesis. Non-responder CHD patients with low S
levels could have an iron supply sufficient to their erythropoietic rate,
and they do not need iron therapy. Low EF even with normal S could
be the most useful index to predict erythroid iron requirement and
response to iron therapy in CHD patients.
Identification of glomernlar immune deposits in essential mixed
crioglobulinemia. Study with anti-idiotypic antibodies. R. A. Sinico, E.
Sabadini, C. 0. Winearls, A. Fornasieri, P. Maldifassi, M. Coppola, A.
Castiglione, 0. D'Amico, Division of Nephrology, San Carlo Hosp,
Milano, Italy, and Dept. of Medicine, RPMS, Hammersmith Hosp,
London, United Kingdom. Renal involvement in essential mixed cryo-
globulinemia (EMC) is likely due to the local deposition of serum
cryoglobulins. However, only indirect evidence supports this hypoth-
esis, as suggested by the finding of the same immunoglobulin classes in
the eryoprecipitates and within the renal immune deposits, by their
characteristic fibrillar appearance at EM examination and by their
antigammaglobulin activity. To provide further and definite evidence of
the nature of the 1gM deposits in EMC-GN, we used 2 mouse mono-
clonal antibodies (MoAb) against cross-reactive idiotypes (CR1) present
on monoclonal rheumatoid factors (M0RFs) from patients with type
II-EMC. MoAb C8201 1 reacted with 9 of 16 circulating IgMk MoREs
tested, and MoAb L8B3 with 4 of the remaining MoRFs. Using indirect
immunofluorescence and/or immunoperoxidase technique we could
identify the same CR1 of the serum MoRE in the renal biopsy specimens
from 11 of 13 patients with EMC-GN. The specificity of the reaction
was controlled by simultaneous processing of sections with unreleavant
MoAbs and by blocking experiments. Kidney specimens from the 3
patients whose MoRF was not recognized by MoAbs C8201 1 and L8B3
were negative. Two of 30 control renal biopsies from patients with other
forms of GN were shown to contain idiotype (C82G 11 and L8B3)
positive material. Both patients had serum polyclonal RF which could
account for this finding. In conclusion, our results provide direct
evidence that serum cryo-MoRF participate in the formation of glomer-
ular immune deposits and, presumably, in the pathogenesis of renal
damage in EMC-GN.
Effects of heparin on glucose-Induced plasma Gil paradoxical increase
in hemodialysis patients. V. Allegra, F. Amendolagine, G. Mengozzi, L.
Jesu, A. Vasile, Servizio Emodialisi, Servizio di Medicina Nucleare,
Laboratorio Analisi, Ospedale di Palmanova, Italy. After glucose load
uremic patients show plasma GH paradoxical increase the causes of
which are unknown. In this investigation we tried to assess the
significance of changes in plasma rate of free fatty acids (FFA) in the
regulation of this anomalous response. In 8 patients under maintenance
hemodialysis we studied plasma GH increase during intravenous glu-
cose tolerance test (IVGTT) carried out in basal conditions and during
continuous infusion of heparin (IVGTT + E), substance which in-
creases FFA plasma rate owing to its action on lipoproteinlipase.
Although the glycemic curves in the two tests can be perfectly super-
imposed, somatotropin incretion appears remarkably inhibited during
IVGTT ÷ E as compared to IVGTT. The heparin infusion prevents
FFA plasma rate fall due to insulin incretion; on the contrary, it
determines a significant increase as compared to basal values. On the
ground of these results and of previous investigations we conclude that
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in uremic patients there is an abnormal glucose sensitivity from specific
hypothalamic regulatory cells. For that reason, in uremic patients FFA
plasma rate changes, which in normal subjects acts only in hypogly-
cemic condition, and acquires significant importance in the regulation of
somatotropin incretion even in euglycemic and hyperglycemic condi-
tions.
Effects of 1,25 (OH) Vitamin D (1,25 1)) in patients with essential
hypertension. F. Mallamaci, C. Zoccali, D. Delfino, S. Parlongo, D.
lellamo, Q. Maggiore., Division of Nephrology and CNR Center of
Clinical Physiology, Reggio Cal, Italy. Marked deviations in plasma
1,25 D inversely related to renin-sodium profile have been described in
patients with essential hypertension. We have investigated the effects of
1,25 D in 11 patients with mild to moderate essential hypertension. The
sterol was administered for two weeks (1 U/day) associated with an oral
calcium supplement (25 mmollday). The design of the study was
randomized, double blind, placebo controlled, crossover and contem-
plated a wash-out of two weeks. Plasma Ca (Radiometer ICA I),
24-hour urinary Ca, serum and urinary phosphate and magnesium, PRA
and arterial pressure (Dinamap 845 with automatic recorder) were
measured on day 0 and on day 14 of each experimental phase. 1 ,25D
caused a consistent increase in plasma Ca (from 1.12 se 0.02 to
1,26 + 0.02 mmol/liter, P < 0.01) as well as in 24-hour urinary Ca
excretion (from 5.9 ÷ 0.7 to 12.3 + 1.1 mmol/liter, P <0.01) while it did
not affect serum and urinary phosphate and magnesium. No change in
any of these measurements was found with placebo. Arterial pressure
rose with 1,25 D (systolic: from 140 + 4.5 to to 148 ÷ 6.3 mm Hg, 90%
confidence interval to 14 mm Hg. diastolic: from 87 + 3 to 93 + 4, 90%
CI 0 toll. MAP: from 104 + 3 to 111 + 4.8, 90% CL Ito 11), but these
changes were unrelated to baseline PRA. Arterial pressure did not
change with placebo. 1,25 D at a dose which causes an increase in
plasma Ca not exceeding the physiological range, has a pressor
action in patients with essential hypertension. Such an effect highlights
the importance of calcium metabolism in the regulation of arterial
pressure. Finally, PRA does not predict the arterial pressure response
to this calcitropic hormone.
Lympho-monokine abnormalities and peritoneal fibroblast proliferation in
patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
S. Carozzi, S. Lamperi, Nephrology Division, St. Martin's Hospital,
Genova, Italy. Studies were performed to see whether or not: I.) perito-
neal T-lymphocytes (PTL) and macrophage (PMØ) secretions, such as
'y-interferon (y-IFN), interleukin-l (IL-l), and prostaglandin E2 (PGE2),
stimulate in vitro proliferation of normal human peritoneal fibroblasts; 2.)
peritoneal ultrafiltration volume in CAPD patients correlates with the
concentrations of the aforementioned secretions in the peritoneal dialysis
effluent (PDE). In vitro studies using a cell culture model showed: a.)
proliferation of normal peritoneal fibroblasts, measured by (3H)-thymidine
incorporation correlated directly with y-IFN and IL-l levels in the PDE
samples added to the cell culture, while no correlation was seen when
-y-IFN was neutralized by a specific monoclonal antibody; b.) proliferation
of normal pentoneal fibroblasts correlated inversely with PGE2 concen-
tration in the PDE samples supplemented to the cell culture. In vivo
studies showed: a.) 'y-IFN and IL-I levels in the PDE correlated inversely
with the peritoneal ultrafiltration volume. We conclude that PL and PMØ
from CAPD patients are able to stimulate in vitro the proliferation of
normal peritoneal fibroblasts through an unbalanced release of lympho-
monokines. Thus, evaluation of PDE concentration of these substances in
CAPD patients may be a tool for early evaluation of ultrafiltration loss and
a way to predict possible sclerotic thickening of pentoneum.
Ultrastructural localization of glomerular anionic sites in human idio-
pathic membranous glomerulonephritis. P. Barsotti, C. Ban grazi, V.
Marinozzi, I Cattedra di Anatomia Patologica, Dipartimento di
Biopatologia Umana, Universitâ "La Sapienza", Roma, Italy. Im-
proved knowledge of the macromolecular organization of glomerular
capillary wall (GCW) has contributed to a better understanding of the
mechanisms involved in a number of pathological conditions, such as
proteinuria or immune complex (IC) diseases. In the present study, the
relationships between GCW anionic sites and IC deposits in human
idiopathic membranous glomerulonephritis (MGN) were investigated.
GCW acidic glycoconjugates were revealed at the electron microscope
level with dialyzed colloidal iron, pH 1.9 (DI). For sulphated groups the
high iron diamine (HID) method was also used. A pre-embedding
staining technique was carried out on 40 jim thick sections obtained
from four, selected needle biopsies. In the first stage of MGN lesion the
newly-formed subepithelial deposits were located in very close contact
with the podocyte plasma membrane. On the other hand, DI and HID
positive sites identical to those seen in the lamina rara externa were
found between the deposits and the lamina densa. In the more advanced
stages the intramembranous deposits were completely surrounded by
negatively charged, DI and HID positive sites. A marked reduction of
the HID positive (that is, sulphated) components of the epithelial cell
coat was also observed. Our data suggest that in MGN the proteinuria
may be due to a structural modification of the whole basement mem-
brane, rather than to a loss of the electrostatic barrier. Actually, as the
MGN lesion progresses, the newly formed basement membrane still
contains prominent anionic charge-rich components. Finally, the close
spatial relationship between the newly formed deposits and the basal
podocyte plasma membrane, as well as the reduction of sulphated
components of the podocyte glycocalix, is in keeping with the view that
antigenic determinants on the surface of the glomerular epithelium may
be relevant in IC formation in human MON.
PTH secretion in initial and final renal failure. D. Rolla, D. Lamperi,
S. Lamperi, Department of Nephrology, San Martin Hospital, Genova,
Italy. Previous studies have shown that Ca2 is the main factor
modulating parathyroid gland PTH secretion. With normal cells, or
adenomatous-hyperplastic parathyroid cells in vitro studies have shown
that Ca2 dependent set point for PTH secretion is different in both
situations. In order to examine the relationship between renal failure
progression and Ca2 dependent set point, we performed PTH suppres-
sion and stimulation tests on 8 patients, with initial renal failure (Group
1: GFR = —30 to 50 mI/mm), on 3 subjects, with final stage renal failure
(Group 2: <10 mI/mm) and on 4 hemodialyzed patients, three times
weekly (Group 3). As regards the undialyzed uremic patients serum
COOH-PTH, serum and intralymphocytic Ca2 values were deter-
mined after Ca-gluconate infusion and after calcium antagonist (diltia-
zem) administration. The same parameters were measured before and
after hemodialysis using a different dyalisate calcium bath (Ca 2,25
mmol/liter and Ca I mmol/liter). We observed different responsiveness
to hypercalcemic suppression in the three groups of patients studied:
the mean PTH decrease was = —48% in Group 1, = —4% in Group
2 and = —6% in Group 3. Serum calcium levels behaved similarly,
while no significant change in intralymphocytic levels was observed.
The stimulation test, performed in Groups 1 and 2 by the administration
of diltiazem, did not cause significant changes in the above parameters.
In Group 3 the stimulation test, performed by intradialytic hypocalce-
mia, showed a slight decrease ( = —2%) in serum Ca2 values in the
patients with less severe hyperparathyroidism. These patients exhibited
no significant change in serum COOH-PTH and intralymphocytic Ca2
levels. Our data show an in vivo rise of the PTH set point which seems
to be correlated to progressively-decreasing renal function. In initial
renal failure, however, the feedback between PTH secretion and serum
Ca2 values enables set point resetting by administration of calcium.
This resetting cannot be achieved in final stage uremic patients before,
or after hemodialysis treatment, because the amount of Ca2+ required
would be at such a high dosage as to be clinically impossible.
Calcium (Ca), phosphate (P) and vitamin D metabolism in essential
hypertension (EH). R. Panebianco, V. Bedogna, E. Valvo, S. Giannini,
L. Malvasi, L. Oldrizzi, C. Rugia, V. Ortalda, G. Barini, S. Adami, A.
Fabris, A. D'Angelo and G. Maschio, Divisione di Nefrologia,
Universitd di Verona; Istituto di Medicina Interna, Universixà di
Padova; and Istituto di Semeiotica Medica, Universitâ di Verona,
Verona, Italy. Alterations in Ca and P metabolism have been observed
in several experimental models of hypertension. Similar defects have
been postulated in human hypertension also. In this study the Ca and P
metabolism was investigated in a group of untreated EH patients, under
basal and stimulated conditions. Fifteen patients, 10 M and 5 F, 32 to 52
years old, with normal renal function, were studied in two different
settings. Patients were hospitalized and submitted to the evaluation of
serum and urine Ca and P, serum Ca, PTH and the vitamin D
metabolites (1.25 D3, 24.25 D3, 25 D3), urine cAMP, muscle Na, K, N
and P content, and the tolerance test to an oral Ca load, after one week
of a diet with normal Ca content (866 mg). The same protocol, plus an
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i.v. P load (3,43 g), was repeated after one week of a diet with low Ca
content (235 mg). Serum and urine Ca and P, PTH, vitamin D
metabolites and cAMP during normal Ca diet were within the normal
range. The changes of these parameters were similar to normal controls
after both the oral Ca load and the low Ca diet. Muscle electrolyte
content was similar to that found in normal subjects. Instead, an
abnormal response to the i.v. P infusion was observed: the percent
fractional excretion of P was higher in EH pts than in normal controls:
21 3 vs. 14 3, P < 0.01. In conclusion, EH pts showed normal Ca
and P metabolism in basal conditions. Only an abnormality in the renal
handling of P during i.v. infusion was observed. Such a "phosphaturic
tubular defect" did not appear to have a clinical relevance and did not
lead to humoral or tissue signs of P depletion.
Inner layer phospholipld (PL) alterations and intraerythrocytary mark-
ers of oxldáttve damage in children with nephrotlc syndrome (NS). F.
Ginevri, G. M. Ghiggeri, R. Oleggini, M. T. Piccardo, R. Bertelli, F.
Perfumo, C. Quejro(o, R. Gusmano, Nephrology Dept., 6. Gaslini
Institute, and Dialysis Section, Hospital of Lavagna, Genoa, Italy.
Inner layer PL, phosphatidylserine (PS) and phosphatidylethanolamine
(PE) are essential for RBC membrane integrity. In view of the reported
RBC charge variation in MCN, we have determined 1.) the PL
composition of RBC ghost, 2.) the influence of serum levels of free fatty
acids (FFA) on RBC PL content, 3.) the intraerythrocytary signals of
oxidative damage: malonyldialdehyde (MDA), fluorescent imino-
propene compounds and glutathione (GSH) in 8 children with minimal
change nephropathy (MCN) (group A), 10 children with steroid unre-
sponsive NS (5 focal glomerular sclerosis, 5 mesangial proliferative
GN) (group B), and in a control group (group N). While ghost PL
composition was normal in group B, in group A major changes of PS
(38.73 9.12 nM/mg Prot. vs. 71.00 10.08) and PE (54.45 6.76
nM/mg Prot. vs. 122.03 29.19) were observed. MDA was very high in
group B (212.6 47.4 nM/mg Hb vs. 90.4 9.8) and only slightly
increased in group A (102.6 14.8); high amounts of fluorescent
inimo-propene compounds were detected in both nephrotic groups.
Accordingly, the intracellular levels of GSI-I were low in both nephrotic
groups (group A 6.74 0.5 nM/mg Hb, group B 5.27 0.4 vs. group N
8.39 0.3). Steroid-induced normalization of proteinuria was followed
b a return to a near normal level of PL concentration and by a parallel
fall of FFA. These data indicate that: in MCN the RBC membrane
shows alterations of PL composition that may be relevant to the
reported charge alterations; signals of peroxidative damage are evident
and can be considered pathogenetic of REC charge alterations; and in
MCN serum FFA are able to modulate the normalization of membrane
PL that follows steroid treatment.
Cardiovascular changes during nocturnal sleep in patients with end-
stage renal failure (ESRF); Preliminary results. A. Sturani, F.
Cirignotta, P. Zucchelli, M. Malpighi, Div,di Nefrologia, and Clinica
Neurologica, Univ. di Bologna, Bologna, Italy. It is well known that
profound and typical changes in circulation and major adjustments in
synipatnetic and in parasympathetic activity occur during sleep. Al-
though derangements in cardiovascular reflexes have been demon-
strated in ESRE patients during wakefulness, research into circulatory
control during sleep is still lacking. The aim of this study is to provide
preliminary information on ESRF patients' hemodynamic pattern dur-
ing sleep, and to verify whether daytime autonomic testing can predict
patient sleep disorder. Six hormotensive ESRF patients, selected
because of normal pulmonary function and neurological examination,
were studied before starting dialysis therapy. Patients underwent a
nocturnal polysomnographic recording with monitoring of intraarterial
blood pressure (BP), ECG, EEG, EOG, ear oxymetry, oro-nasal,
thoracic and abdominal respiration. During wakefulness sympathetic
and parasympathetic activitiy were evaluated using a series of standard-
ized cardiovascular reflex function tests and plasma noradrenaline (NA)
determination, within 7 days of the nocturnal polysomnographic record-
ing. All patients showed a disrupted sleep pattern without significant
oxygen desaturation or breathing abnormalities. In all the patients, BP
decreased progressively during nonREM sleep, returning to wakeful-
ness values during REM sleep as per normal. Sudden, very frequent
swings in BR (>20 for systolic and >10 mm Hg for diastolic) were
observed during each sleep stage in 4 patients with a normal response to
sympathetic tests, but with higher NA values (258 to 392 range) than in
controls (164 88 M SD and in the other 2 patients (43 and 100). No
significant changes occurred in heart rate during sleep in the 6 patients
even though a parasympathetic deficit was present in only 2 patients. In
conclusion, in ESRF patients, a high BP variability during sleep seems
to be associated to a sympathetic hyperactivity. An abnormal heart rate
behavior occurs irrespective of a preserved parasympathetic function.
Bone formation rate in uremic patients with positive aluminum stain in
bone blopsies Correlation with parathyrold activity. G. Rombold, G.
Colussi, M. E. De Ferrari, E. Minola, M. Surian, L. Minetti, Renal and
Pathology Units, Ospedale Niguarda, Milan, Italy. The surface depo-
sition of Al in bone of dialysis patients is usually associated with
abnormal mineralization rate, though normal mineralization may exist
in some patients. We have analyzed clinical, biochemical and histolog-
ical parameters in 32 patients with positive bone histocheinical staining
for Al (20 to 100% trabecular bone surface): bone histology showed
pure osteomalacia in 13, mixed lesions in 11, aplastic bone disease in 5
and osteitis fibrosa in 3. Twenty-one patients (pts A) had abnormal bone
formation rate (BFRt 0.002 to 0.1 s/2/day), while in 11 of 32 (pts B)
BFRt (0.11 to 0.81) was similar to the values observed in 19 additional
patients with negative bone Al staining (BFR 0.429 0.25). Pts A had
lower (l-84)PTH levels (5.9 3.2 pmol/ml vs. 26.6 29, P < 0.02) and
osteoclasts (0.48 0.7/nun2 vs. 1.66 2, P < 0.02), than pts B. The
percent Al-positive trabecular surface in pts A (69.3 21.6) was higher
than in pts B (39 26, P < 0.01). Plasma Ca (10.2 0.66 vs. 10 0.8
mgldl), P (4.7 1.5 vs. 3.8 1.9 mg/dl), Mg (3.6 1.5 vs. 3.1 mg/dl)
and alkaline phosphatase (174 82 vs. 244 53 lU/liter) were not
different. There was a slight correlation between the percent Al-
positive trabecular surface and BFRt (r = 0.44, P < 0.05); BFRt was
also highly significantly correlated with (1-84). PTH (r 0.89, P <
0.001) and osteoclasts (r = 0.83, P < 0.001) in patients with negative
bone Al staining, and all the patients with positive bone Al stain fell
within the 95% confidence limits of that relationships. In conclusion, it
appears that both Al bone burden and parathyroid activity are impor-
tant determinants of bone mineralization rate in uremic patients; a
normal mineralization rate may be maintained despite Al deposition in
bone if parathyroid activity is not concomitantly reduced.
Changes in cardiac performances in hemodialysis patients treated with
human recombinant erythropoietln. R. Mangiarotti, A. Pierini, S.
Casati, P. Passerini, G. C. Ambroso, C. Pini, G. Graziani. Divisione di
Nefrologia and Istituto di Patologia Medica, Ospedale Maggiore
Policlinico, Milan, Italy. In six chronic hemodialysis patients (mean age
44 13 years; range 26 to 60 yrs) treated with human recombinant
erythropoietin (rHuEPO) mono-bidimension echocardiography investi-
gation (MbEcho) was performed to evaluate the changes in cardiac
performances. Pre- and post-dialysis MbEcho was performed before
rHuEPO treatment (Do) (Hb 6.1 0.7 g/d1) at 50% of the desired Hb
increment (D 50) (Hb 9,4 0.9 g/dl) and at correction of anemia (D 100)
(Hb 12.1 1.1 g/dl). Predialysis left ventricular end diastolic diameter
(LVED) was 57 1.2mm at Do and reduced to 53.5 1.4mm at D 50
(P <0.05), while no further reduction was observed at D 100(51.1 1.1
mm). Before ri-IuEPO treatment predialysis LVED was 57 1 mm and
shortened to 52 2 mm post-dialysis (P < 0.05). When correction of
anemia was achieved, pre- and post-dialysis LVED did not differ (53.1
1.1 vs. 50 1 mm; P = NS). The remaining indices of heart
coniractility (fractional shortening, mean velocity of circumferential
fiber shortening, PEP/LVET ratio) did not change. Mean heart rate
lowered from 82.4 1.4 to 65.6 4.3 bpm at D 50 (P <0.05) and to 64.3
5.6 bpm at D 100. In one patient predialysis LVED lengthened from
44 mm to 55 mm and heart rate rose from 56 to 64 bpm. It is concluded
that the correction of anemia by rHuEPO induced favorable hemody-
namic changes with reduction of predialysis LVED without increase in
heart contractility. These data, together with a non-significantpre-post-
dialysis reduction of LVED, confirm the improved cardiac adaptation
to dialysis. However, if the correction of anemia is not accompanied
by an early reduction of predialysis LVED, greater hemoglobin incre-
ments do not improve left ventricular function. This event might be
explained as poor adaptation of the cardiovascular system to the
increased circulating red cell mass and may induce cardiovascular
complications.
